Gatifloxacin
Top View
- Development of New Novel Bacterial Topoisomerase Inhibitors As Promising Antibiotics with a 5-Amino-1,3-Dioxane Linker Moiety DI
- Anatomical Classification Guidelines V2018 EPHMRA ANATOMICAL
- Adverse Effects of Antimicrobials Via Predictable Or Idiosyncratic Inhibition of Host Mitochondrial Components Alison E
- Mycobacterium Tuberculosis DNA Gyrase As a Target for Drug Discovery
- Inhibitors of Nucleic Acid Synthesis the Antibacterial Drugs That Inhibit
- 021493 Gatifloxacin Clinical BPCA
- Sem-V-Cbcs –Ay 2020-21 Subject: Bph C 504 T- Pharmacology
- Sterile Ophthalmic Solution Antibacterial Agent Apotex I
- Emerging Drugs for Active Tuberculosis
- Reptb: a Gene Ontology Based Drug Repurposing Approach for Tuberculosis Anurag Passi1,2, Neeraj Kumar Rajput1, David J
- Elevated Gatifloxacin and Reduced Rifampicin Concentrations in a Single
- E.Johnson Supplementary
- A Multi-Center Randomized Trial to Assess the Efficacy of Gatifloxacin Versus Ciprofloxacin for the Treatment of Shigellosis in Vietnamese Children
- General Items
- A Novel Predictive Model for the Anti-Bacterial, Anti-Malarial and Herg Cardiac QT Prolongation Properties of Fluoroquinolones Clifford Fong
- (12) Patent Application Publication (10) Pub. No.: US 2015/0024048A1 Hemmingsen Et Al
- Anti-Leprosy Drugs: Modes of Action and Mechanisms of Resistance in Mycobacterium Leprae
- Quinolones and Fluoroquinolones Art. 31